Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, will be attending a series of meetings in the following week, where he will be discussing bioscience innovations powered by AI and robotics.
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, will be attending a series of meetings in the following week, where he will be discussing bioscience innovations powered by AI and robotics.
More information about the events is listed as follows:
Fireside Chat: The Forefront of AI Innovation in Health Tech
Time: Monday, 10th June 15:55 – 16:15 (UK time)
Location: London Olympia, Main Stage
London Tech Week is the global tech ecosystem aiming to accelerate the infinite cycle of tech innovation, which brings together the innovators creating the technologies of the future, the investors who fund them and the enterprise tech leaders who adopt them.
With over 90 countries represented, London Tech Week 2024 focuses on key themes including artificial intelligence, the deep tech revolution and green innovation, with 45,000 attendees gathering across the week.
[2] Founders Forum Global & Founders Longevity Forum
Session: Bioscience Breakthroughs: The Path to Healthier Lives and Longevity
Time: Thursday, 13th June, 11:25 AM – 12:05 PM (UK time)
Location: Soho Farmhouse, UK
Founders Forum Group is a global community and group of businesses empowering entrepreneurs started in 2005. Since then, it has hosted over 40 forums in more than 20 cities worldwide, hoping to foster collaboration and innovation.
In its 18th edition, Founders Forum Global 2024 connects 400+ trailblazing founders and 130 world-class VCs representing $1.5 trillion AUM, encompassing 60 sectors and 35 countries all over the world.
Fireside Chat: How AI is accelerating drug discovery, commercialization and licensing models.
Time: Monday 11 June 12:15pm (UK time)
Location: London Olympia
Designed to bring together founders and CEOs, venture capitalists, corporate venture capitalists, family offices, and global thought leaders, Founders Longevity Forum aim to establish connections and ignite innovation in the longevity tech field. In 2024, the event will be held during London Tech Week, the lively global technology gathering.
Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets and has received clinical trial approval for seven molecules. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients.
About Insilico Medicine
Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.co
